• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Mallinckrodt receives clearance for OptiMark

Article

Mallinckrodt is eyeing a broader piece of the MRI contrast market, thanks to recent Food and Drug Administration clearance of its OptiMark contrast agent. OptiMark is designed for use in MR imaging of lesions and tumors of the brain, spine, and liver.The

Mallinckrodt is eyeing a broader piece of the MRI contrast market, thanks to recent Food and Drug Administration clearance of its OptiMark contrast agent. OptiMark is designed for use in MR imaging of lesions and tumors of the brain, spine, and liver.

The segment of the MR market into which OptiMark will be sold is worth more than $150 million annually and is growing at a rate of 12% to 15%, according to the St. Louis-based vendor. Mallinckrodt already sells another MR contrast agent, GastroMark, for use in imaging of the gastrointestinal tract. The company expects to begin shipping OptiMark this quarter.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.